Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7447)
All Articles published online
|
Publishing Process of This Article
|
Dec 21, 2013 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World J Gastroenterol 2013; 19(47): 8940-8948 [PMID: 24379619 DOI: 10.3748/wjg.v19.i47.8940] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i47/8940.htm |
| Number | Citing Articles |
| 1 |
Surasak Jittavisutthikul, Jeeraphong Thanongsaksrikul, Kanyarat Thueng-in, Monrat Chulanetra, Potjanee Srimanote, Watee Seesuay, Aijaz Malik, Wanpen Chaicumpa. Humanized-VHH Transbodies that Inhibit HCV Protease and Replication. Viruses 2015; 7(4): 2030 doi: 10.3390/v7042030
|
| 2 |
Tatsuo Kanda, Kazushige Nirei, Naoki Matsumoto, Teruhisa Higuchi, Hitomi Nakamura, Hiroaki Yamagami, Shunichi Matsuoka, Mitsuhiko Moriyama. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World Journal of Gastroenterology 2017; 23(46): 8120-8127 doi: 10.3748/wjg.v23.i46.8120
|
| 3 |
Hubert G. M. Niesters, Annelies Riezebos-Brilman, Coretta C. Van Leer-Buter. Manual of Molecular and Clinical Laboratory Immunology. 2016; : 620 doi: 10.1128/9781555818722.ch65
|
| 4 |
Andrea Magri, Alexander A. Ozerov, Vera L. Tunitskaya, Vladimir T. Valuev-Elliston, Ahmed Wahid, Mario Pirisi, Peter Simmonds, Alexander V. Ivanov, Mikhail S. Novikov, Arvind H. Patel. Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication. Scientific Reports 2016; 6(1) doi: 10.1038/srep29487
|
| 5 |
Anusorn Kiattanaphon, Yaovaluk Vipsoongnern, Duangkamol Kunthalert, Anchalee Sistayanarain. Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a. Molecular Biology Reports 2022; 49(10): 9437 doi: 10.1007/s11033-022-07803-5
|
| 6 |
Midori Kjellin, Terése Wesslén, Erik Löfblad, Johan Lennerstrand, Anders Lannergård. The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. Upsala Journal of Medical Sciences 2018; 123(1): 50 doi: 10.1080/03009734.2018.1441928
|
| 7 |
Betsaida Bibo‐Verdugo, Zhenze Jiang, Conor R. Caffrey, Anthony J. O'Donoghue. Targeting proteasomes in infectious organisms to combat disease. The FEBS Journal 2017; 284(10): 1503 doi: 10.1111/febs.14029
|
| 8 |
Aravindhan Ganesan, Khaled Barakat. Applications of computer-aided approaches in the development of hepatitis C antiviral agents. Expert Opinion on Drug Discovery 2017; 12(4): 407 doi: 10.1080/17460441.2017.1291628
|
| 9 |
Tatsuo Kanda, Osamu Yokosuka, Masao Omata. Faldaprevir for the Treatment of Hepatitis C. International Journal of Molecular Sciences 2015; 16(12): 4985 doi: 10.3390/ijms16034985
|
| 10 |
Lize Cuypers, Francesca Ceccherini‐Silberstein, Kristel Van Laethem, Guangdi Li, Anne‐Mieke Vandamme, Jürgen Kurt Rockstroh. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Reviews in Medical Virology 2016; 26(6): 408 doi: 10.1002/rmv.1895
|
| 11 |
Kittirat Glab-ampai, Monrat Chulanetra, Aijaz Ahmad Malik, Thanate Juntadech, Jeeraphong Thanongsaksrikul, Potjanee Srimanote, Kanyarat Thueng-in, Nitat Sookrung, Pongsri Tongtawe, Wanpen Chaicumpa. Human single chain-transbodies that bound to domain-I of non-structural protein 5A (NS5A) of hepatitis C virus. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-14886-9
|
| 12 |
Seyed Arad Moghadasi, Morgan A. Esler, Yuka Otsuka, Jordan T. Becker, Sofia N. Moraes, Constance B. Anderson, Srinivas Chamakuri, Christopher Belica, Chloe Wick, Daniel A. Harki, Damian W. Young, Louis Scampavia, Timothy P. Spicer, Ke Shi, Hideki Aihara, William L. Brown, Reuben S. Harris, Jacob Yount.
Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M
pro
/3CL
pro
in Living Cells
. mBio 2022; 13(3) doi: 10.1128/mbio.00784-22
|
| 13 |
Aqsa Ikram, Ayesha Obaid, Faryal Mehwish Awan, Rumeza Hanif, Anam Naz, Rehan Zafar Paracha, Amjad Ali, Hussnain Ahmed Janjua. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine. Antiviral Research 2017; 137: 112 doi: 10.1016/j.antiviral.2016.10.013
|
| 14 |
Navaneethan Palanisamy, Johan Lennerstrand. Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach. Interdisciplinary Sciences: Computational Life Sciences 2018; 10(1): 143 doi: 10.1007/s12539-016-0177-4
|
| 15 |
Ying Cao, Yi Bao, Wei Xia, Hao Wu, Feili Wei, Yu Zhang, Renwen Zhang, Xiaoyuan Xu. Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients. Clinics and Research in Hepatology and Gastroenterology 2016; 40(5): 597 doi: 10.1016/j.clinre.2016.02.004
|
| 16 |
Luísa Hoffmann, Débora Souza Faffe, Jennifer Fróes Cruz Lima, Thayanna Araujo Capitanio, Bianca Catarina Azeredo Cabral, Turán Péter Ürményi, Henrique Sergio Moraes Coelho, Edson Rondinelli, Cristiane Alves Villela-Nogueira, Rosane Silva. No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy. BBA Clinical 2015; 3: 146 doi: 10.1016/j.bbacli.2015.01.004
|
| 17 |
Evelyn J. Franco, George L. Drusano, Kaley C. Hanrahan, Kelly L. Warfield, Ashley N. Brown. Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression. Viruses 2023; 15(5): 1175 doi: 10.3390/v15051175
|
| 18 |
Thitiya Boonma, Bodee Nutho, Thanyada Rungrotmongkol, Nadtanet Nunthaboot. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective. Computational Biology and Chemistry 2019; 83: 107154 doi: 10.1016/j.compbiolchem.2019.107154
|
| 19 |
Tatsuya Aikawa, Chisato Ueno, Yohko Kikuchi, Fumio Tsuda, Hiroshi Ohnishi, Hiroaki Okamoto. Direct-acting antiviral agent-resistant mutants in patients with type C chronic liver diseases: Detection and its clinical significance. Kanzo 2015; 56(11): 621 doi: 10.2957/kanzo.56.621
|
| 20 |
Qi-Fei Zhong, Rui Liu, Gang Liu. Structure–activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870. Molecular Diversity 2015; 19(4): 829 doi: 10.1007/s11030-015-9610-6
|
| 21 |
Kittirat Glab-ampai, Aijaz Ahmad Malik, Monrat Chulanetra, Jeeraphong Thanongsaksrikul, Kanyarat Thueng-in, Potjanee Srimanote, Pongsri Tongtawe, Wanpen Chaicumpa. Inhibition of HCV replication by humanized-single domain transbodies to NS4B. Biochemical and Biophysical Research Communications 2016; 476(4): 654 doi: 10.1016/j.bbrc.2016.05.109
|
| 22 |
Nicasio Mancini, Lara Marrone, Nicola Clementi, Giuseppe A Sautto, Massimo Clementi, Roberto Burioni. Adoptive T-cell therapy in the treatment of viral and opportunistic fungal infections. Future Microbiology 2015; 10(4): 665 doi: 10.2217/fmb.14.122
|
| 23 |
Amanda L Aloia, Nicholas S Eyre, Stuart Black, Stephen J Bent, Adriana Gaeguta, Zhuyan Guo, Sumudu K Narayana, Robert Chase, Stephen Locarnini, Jill M Carr, John A Howe, Michael R Beard. Generation of a Chimeric Hepatitis C Replicon Encoding a Genotype-6a NS3 Protease and Assessment of Boceprevir (SCH503034) Sensitivity and Drug-Associated Mutations. Antiviral Therapy 2015; 20(3): 271 doi: 10.3851/IMP2850
|
| 24 |
Ruben Brandão, Rute Marcelino, Fátima Gonçalves, Isabel Diogo, Ana Carvalho, Joaquim Cabanas, Inês Costa, Pedro Brogueira, Fernando Ventura, Ana Miranda, Kamal Mansinho, Perpétua Gomes. Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort. Viruses 2018; 10(5): 223 doi: 10.3390/v10050223
|
| 25 |
Ying Cao, Yu Zhang, Yi Bao, Renwen Zhang, Xiaxia Zhang, Wei Xia, Hao Wu, Xiaoyuan Xu. Naturally occurring hepatitis C virus protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV co-infection. Hepatology Research 2016; 46(6): 552 doi: 10.1111/hepr.12590
|
| 26 |
Jingshu Zhang, Yun Lan, Sumana Sanyal. Modulation of Lipid Droplet Metabolism—A Potential Target for Therapeutic Intervention in Flaviviridae Infections. Frontiers in Microbiology 2017; 8 doi: 10.3389/fmicb.2017.02286
|
| 27 |
John A. Howe, Jianmin Long, Stuart Black, Robert Chase, Patricia McMonagle, Stephanie Curry, Seth Thompson, Mark J. DiNubile, Anita Y. M. Howe. Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin. Open Forum Infectious Diseases 2014; 1(2) doi: 10.1093/ofid/ofu078
|
| 28 |
Rita C.F. Tavares, Ana C.C.A. Feldner, João R.R. Pinho, Silvia N.O. Uehara, Christini T. Emori, Roberto J. Carvalho-Filho, Ivonete S.S. Silva, Rúbia A.F. Santana, Vanessa F.D. de Castro, Gregório T. F. Castoli, Charliana U. Cristovão, Maria L.C.G. Ferraz. Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection. European Journal of Gastroenterology & Hepatology 2017; 29(7): 754 doi: 10.1097/MEG.0000000000000866
|
| 29 |
Zhe Jiao, Yuanyuan Yan, Yixi Chen, Gang Wang, Xiaowei Wang, Lisha Li, Mengfang Yang, Xiaoshuai Hu, Yilin Guo, Yuejun Shi, Guiqing Peng, Tom Gallagher. Adaptive Mutation in the Main Protease Cleavage Site of Feline Coronavirus Renders the Virus More Resistant to Main Protease Inhibitors. Journal of Virology 2022; 96(17) doi: 10.1128/jvi.00907-22
|
| 30 |
Surasak Jittavisutthikul, Watee Seesuay, Jeeraphong Thanongsaksrikul, Kanyarat Thueng-in, Potjanee Srimanote, Rolf G. Werner, Wanpen Chaicumpa. Human Transbodies to HCV NS3/4A Protease Inhibit Viral Replication and Restore Host Innate Immunity. Frontiers in Immunology 2016; 7 doi: 10.3389/fimmu.2016.00318
|